Convergent Genomics
Convergent Genomics is a genomic diagnostic company focused on transforming urologic cancer care through advanced genomics and machine learning. Their primary product, UroAmp, is a non-invasive genomic urine test designed to detect, monitor, and predict the risk of urothelial cancer and its recurrence significantly earlier than current standards of care. UroAmp analyzes DNA from urine, interrogating key genes and whole-genome changes to provide actionable insights for personalized patient management. The company leverages next-generation sequencing and a patented Enhanced Preservation Media (EPM) to ensure sample integrity and high-quality results, aiming to change the timeline for cancer detection and improve patient outcomes.
Convergent Genomics
Convergent Genomics is a genomic diagnostic company focused on transforming urologic cancer care through advanced genomics and machine learning. Their primary product, UroAmp, is a non-invasive genomic urine test designed to detect, monitor, and predict the risk of urothelial cancer and its recurrence significantly earlier than current standards of care. UroAmp analyzes DNA from urine, interrogating key genes and whole-genome changes to provide actionable insights for personalized patient management. The company leverages next-generation sequencing and a patented Enhanced Preservation Media (EPM) to ensure sample integrity and high-quality results, aiming to change the timeline for cancer detection and improve patient outcomes.